TABLE 2.

Heterogeneity and horizontal pleiotropy analysis.

Exposure	Outcome	Heterogeneity			Horizontal pleiotropy
					MR–PRESSO test		MR–Egger regression
		Q	Q df	P	Global Test RSSobs	Global Test P	intercepts (95% CI)	P
BMI
	T2DM	2867.057	445	< 0.001	2885.029	< 0.001	−0.001 (0.994,1.005)	0.837
	HOMA-IR	510.260	446	0.019	512.445	0.023	0 (0.998,1.001)	0.430
	HbA1c	654.863	445	< 0.001	658.515	< 0.001	0 (0.999,1)	0.714
	Fasting insulin	624.170	448	< 0.001	626.889	< 0.001	0 (0.999,1.001)	0.842
	Fasting glucose	619.187	448	< 0.001	622.082	< 0.001	0 (0.999,1.001)	0.838
WHR
	T2DM	1718.377	275	< 0.001	1739.466	< 0.001	0.008 (1,1.017)	0.055
	HOMA-IR	368.360	277	< 0.001	371.364	< 0.001	0 (0.998,1.002)	0.729
	HbA1c	413.286	279	< 0.001	416.611	< 0.001	0 (0.999,1.001)	0.695
	Fasting insulin	431.511	280	< 0.001	435.262	< 0.001	0 (0.998,1.002)	0.853
	Fasting glucose	358.324	280	0.001	361.045	0.001	0 (0.998,1.002)	0.935
WHRadjBMI
	T2DM	1590.053	236	< 0.001	1609.124	< 0.001	0.003 (0.995,1.011)	0.455
	HOMA-IR	290.496	237	0.010	293.251	0.011	−0.001 (0.997,1.001)	0.175
	HbA1c	383.587	238	< 0.001	387.452	< 0.001	0 (0.999,1)	0.355
	Fasting insulin	362.009	239	< 0.001	365.491	< 0.001	−0.002 (0.997,1)	0.029
	Fasting glucose	276.448	239	0.048	278.957	0.047	−0.001 (0.998,1.001)	0.319

WHR, waist-to-hip ratio; BMI, body mass index; WHRadjBMI, waist-to-hip ratio adjusted for body mass index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; T2DM, Type 2 diabetes; SD, standard deviation; HOMA-IR, Homeostasis model assessment of insulin resistance; HbA1c, Hemoglobin A1c; Q, Cochran’s Q test estimate; df, Cochran’s Q test degrees of freedom; MR–egger, Mendelian randomization–Egger regression; MR–PRESSO, Mendelian randomization pleiotropy residual sum and outlier method; OR, odds ratio; CI, confidence interval.